Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

719 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Patterns of transmitted HIV drug resistance in Europe vary by risk group.
Frentz D, van de Vijver D, Abecasis A, Albert J, Hamouda O, Jørgensen L, Kücherer C, Struck D, Schmit JC, Vercauteren J, Asjö B, Balotta C, Bergin C, Beshkov D, Camacho R, Clotet B, Griskevicius A, Grossman Z, Horban A, Kolupajeva T, Korn K, Kostrikis L, Linka KL, Nielsen C, Otelea D, Paraskevis D, Paredes R, Poljak M, Puchhammer-Stöckl E, Sönnerborg A, Stanekova D, Stanojevic M, Vandamme AM, Boucher C, Wensing A; SPREAD Programme. Frentz D, et al. Among authors: paredes r. PLoS One. 2014 Apr 10;9(4):e94495. doi: 10.1371/journal.pone.0094495. eCollection 2014. PLoS One. 2014. PMID: 24721998 Free PMC article.
High-dose saquinavir plus ritonavir: long-term efficacy in HIV-positive protease inhibitor-experienced patients and predictors of virologic response.
Paredes R, Puig T, Arnó A, Negredo E, Balagué M, Bonjoch A, Jou A, Tuldrà A, Tural C, Sirera G, Veny A, Romeu J, Ruiz L, Clotet B. Paredes R, et al. J Acquir Immune Defic Syndr. 1999 Oct 1;22(2):132-8. doi: 10.1097/00126334-199910010-00004. J Acquir Immune Defic Syndr. 1999. PMID: 10843526 Clinical Trial.
Prospective randomized two-Arm controlled study to determine the efficacy of a specific intervention to improve long-term adherence to highly active antiretroviral therapy.
Tuldrà A, Fumaz CR, Ferrer MJ, Bayés R, Arnó A, Balagué M, Bonjoch A, Jou A, Negredo E, Paredes R, Ruiz L, Romeu J, Sirera G, Tural C, Burger D, Clotet B. Tuldrà A, et al. Among authors: paredes r. J Acquir Immune Defic Syndr. 2000 Nov 1;25(3):221-8. doi: 10.1097/00126334-200011010-00003. J Acquir Immune Defic Syndr. 2000. PMID: 11115952 Clinical Trial.
Leishmaniasis in HIV-infected persons: a review.
Paredes R, Laguna F, Clotet B. Paredes R, et al. J Int Assoc Physicians AIDS Care. 1997 Jun;3(6):22-39. J Int Assoc Physicians AIDS Care. 1997. PMID: 11364428
Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with hiv-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study.
Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balagué M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J, Clotet B; Spanish Lipodystrophy Group. Ruiz L, et al. Among authors: paredes r. J Acquir Immune Defic Syndr. 2001 Jul 1;27(3):229-36. doi: 10.1097/00126334-200107010-00003. J Acquir Immune Defic Syndr. 2001. PMID: 11464141 Clinical Trial.
Leishmaniasis in HIV infection.
Paredes R, Munoz J, Diaz I, Domingo P, Gurgui M, Clotet B. Paredes R, et al. J Postgrad Med. 2003 Jan-Mar;49(1):39-49. doi: 10.4103/0022-3859.929. J Postgrad Med. 2003. PMID: 12865570 Free article. Review.
Benefit of switching from a protease inhibitor (PI) to nevirapine in PI-experienced patients suffering acquired HIV-related lipodystrophy syndrome (AHL): interim analysis at 3 months of follow-up.
Negredo E, Paredes R, Bonjoch A, Tuldrà A, Fumaz CR, Gel S, Garcés B, Johnston S, Arnó A, Balagué M, Jou A, Tural C, Sirera G, Romeu J, Cruz L, Francia E, Domingo P, Arrizabalaga J, Ruiz I, Arribas JR, Ruiz L, Clotet B. Negredo E, et al. Among authors: paredes r. Antivir Ther. 1999;4 Suppl 3:23-8. Antivir Ther. 1999. PMID: 16021868 Clinical Trial.
719 results